IG
NAVB

ING Group’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

ING Group’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-60,000
Closed -$1.75M – 689
2014
Q2 		$1.75M Hold
60,000
– – 0.01% 471
2014
Q1 		$2.23M Buy
+60,000
New +$2.28M 0.01% 468

Other funds holding NAVB

PM
Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ING Group's NAVB Position: Q3 2014 in Review

ING Group sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q3 2014, closing a stake of 60,000 shares — an estimated $1.75M sold.

ING Group first reported a position in NAVB in Q1 2014 and held it in 2 quarters. The position peaked at $2.23M in Q1 2014. 81 funds tracked by Wall St. Rank hold NAVB as of Q3 2014.

  • ING Group reported no remaining Navidea Biopharmaceuticals Inc. position as of Q3 2014 after selling out during the quarter.
  • ING Group sold 60,000 Navidea Biopharmaceuticals Inc. shares in Q3 2014, an estimated $1.75M.
  • ING Group first reported a position in Navidea Biopharmaceuticals Inc. in Q1 2014 and held it in 2 quarters.
  • ING Group's Navidea Biopharmaceuticals Inc. position peaked at $2.23M in Q1 2014.
  • 81 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q3 2014.

Based on ING Group's 13F filing for Q3 2014, filed 14 Nov 2014.